Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-4055 in metastatic malignant melanoma
NCT00232726Phase 2Completed
- Sponsor
- Clavis Pharma
- Start
- Sep 2005
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of elacytarabine in Malignant Melanoma (MM), sponsored by Clavis Pharma. Primary endpoint: Objective tumour response. Started Sep 2005; status: completed.
02
Drugs
elacytarabine
03
Conditions
Malignant Melanoma (MM)
Beyond the preview
Go deeper on NCT00232726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232726.